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Abstract 
Non-alcoholic fatty liver disease (NAFLD) is a fast-growing silent epidemic that is present in both developed and 
developing countries. Initially thought as a benign deposition of lipids in the liver, it now has been shown to be a 
major risk factor for type II diabetes and one of the leading causes of cirrhosis. Recent findings suggest that dysregula-
tion of mitochondrial homeostasis and autophagy play critical roles in the hepatocyte injury and insulin resistance of 
NAFLD. Thyroid hormone (TH) is a major stimulator of hepatic autophagy and mitochondrial function. Decreased TH 
action has been associated with NAFLD in man. In this review, we highlight some of the new discoveries that demon-
strate the roles of TH in hepatic mitochondrial homeostasis via mitophagy and their implications for NAFLD.
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Background
Non-alcoholic fatty liver disease (NAFLD) is initiated 
by lipid accumulation in hepatocytes [1, 2] that leads 
to a spectrum of liver dysfunction ranging from excess 
lipid storage in the liver (hepatosteatosis) to progres-
sive non-alcoholic steatohepatitis (NASH), that in turn, 
increases the risk for cirrhosis and hepatocellular can-
cer. NAFLD occurs in 25–35 % of the general US. popu-
lation, and its prevalence is estimated to be 60–80 % in 
patients with type II diabetes milletus (DM) and obesity 
[2]. In addition to causing hepasteatosis and inflamma-
tion within the liver, NAFLD also can have profound 
metabolic effects by inducing hepatic insulin resistance 
[3]. Additionally, defects in β-oxidation of fatty acids and 
lipotoxicity owing to intracellular over-accumulation 
of fatty acids and their toxic metabolites are thought to 
play important roles in the pathogenesis of NAFLD [1, 2]. 
The progression in NAFLD often leads to insulin resist-
ance, increased hepatic glucose production, and wors-
ened glycemic control in diabetic patients, resulting in a 
vicious cycle that further exacerbates the manifestations 
and complications of diabetes. Unfortunately, little is 
known about hormonal regulation of hepatosteatosis and 
gluconeogenesis in NAFLD or the roles of hormones in 
disease progression. Moreover, although there are many 
drug therapy options for treating hyperglycemia in diabe-
tes; currently, there are no effective drug treatments for 
NAFLD.
Thyroid hormones (THs: T3, T4) promote the oxi-
dation of fatty acids within the liver, so it is possible 
that impaired TH action in the liver may contribute to 
NAFLD. Indeed, it recently has been shown that the inci-
dence of NAFLD is doubled in patients with hypothy-
roidism [4] with approximately 15  % patients affected. 
Additionally, T3 and several TH analogs can ameliorate 
NAFLD in rodents that are fed high fat diet (HFD) [5, 6]. 
At the genomic level, many of the genes that have altered 
expression in NAFLD are regulated by TH [7], further 
supporting the notion that defects in TH signaling may 
promote hepatosteatosis and hepatic damage. Two recent 
studies also have shown that thyroid hypofunction occurs 
with higher frequency in both young and elderly adults 
with NAFLD [8, 9].
T3 stimulates the conversion of triglycerides to free 
fatty acids for delivery into the mitochondria by increas-
ing mRNA expression and activities of hepatic lipases 
[10]. While this process is well described, it is possible 
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that other cellular pathways may be involved in the deliv-
ery of stored triglycerides from lipid droplets to mito-
chondria. Recently, autophagy has been shown to 
promote cell survival during nutrient deprivation and 
upon exposure to inflammatory or pro-apoptotic stimuli 
[11, 12]. Moreover, autophagy has been implicated in the 
direct catabolism of fatty acids through “lipophagy” [13] 
and inhibition of autophagy leads to the development 
of fatty liver and insulin resistance [14]. We previously 
showed that T3 stimulated hepatic fatty acid oxidation 
through lipophagy [15]. We and others also have showed 
that T3 and TH analogs can decrease hepatosteatosis in 
cell culture and in rodent models [5, 6, 15]. The accom-
panying increase in oxidative phosphorylation leads to 
increased mitochondrial reactive oxygen species (ROS) 
production that can cause mitochondrial damage and cell 
death [16].
TH stimulates mitophagy and mitochondrial 
biogenesis
The major mechanisms for mitochondrial repair are 
mitochondrial fusion, fission, and mitochondrial 
autophagy or “mitophagy” [17]. To determine the occur-
rence of mitophagy, we used a tandem-tagged RFP-EGFP 
chimeric plasmid, pAT016, encoding a mitochondria 
targeting signal sequence fused in-frame with RFP and 
EGFP genes (tandem tagged Mito-mRFP-EGFP). RFP 
and GFP have different stabilities in an acidic environ-
ment [18]. The GFP signal is quenched at lower pH 
whereas RFP can be visualized in acidic autolysosomes; 
thus, increased RFP/red-only fluorescence in the lys-
osomes indicates completion of the mitophagic process 
(Fig. 1a). Using this assay, we observed that T3 increased 
autolysosome-resident mitochondria (red fluorescent 
dots without any green fluorescence) at concentrations 
as low as 1 nM and as early as 24 h (Fig. 1b, c). We then 
conducted studies of autophagy in primary mouse hepat-
ocytes. T3 induced autophagic flux and mitophagy in pri-
mary mouse hepatocytes observed mitochondrial protein 
accumulation and the presence of autophagosome-res-
ident mitochondria by electron microscopy (Fig.  1d, e). 
These findings demonstrate that these cell-autonomous 
effects occurred in primary hepatic cells with normal 
TRβ expression. Similar effects for autophagic flux also 
were seen in cell culture and in mice treated with the lys-
osomal inhibitor, chloriquine.
Mitochondrial translocation of the autophagic machin-
ery is required for mitophagy so we measured the levels 
of autophagic proteins in purified mitochondrial frac-
tions that were verified to be free from cytosolic and lys-
osomal contamination (Fig.  2a). T3 treatment increased 
the localization of Ubiquitin-like protein 1 (ULK1), p62, 
and LC3II within the mitochondrial fraction of HepG2 
cells. Dynamin 1-like protein (Drp1), a protein associated 
with mitochondrial fission and mitophagy also was pref-
erentially recruited to mitochondria after T3 treatment 
(Fig.  2a). Additionally, increased mitochondrial protein 
ubiquitination was observed in T3-treated cells (Fig. 2a) 
consistent with the notion that mitochondrial ubiquitina-
tion precedes mitophagy. Confocal imaging of mt-RFP-
EGFP in conjunction with the mitochondrial marker, 
TOMM20, showed that T3 increased mitophagy. How-
ever, treatment with ULK1 siRNA decreased mitophagy 
induced by T3 back to baseline level. Thus, mitophagy 
critically depends upon ULK1 and suggests that the lat-
ter is a necessary component for forming the nascent 
autophagosome that engulfs mitochondria (Fig.  2b, 
c) [16]. Interestingly, siRNA knockdown of ULK1 did 
not abrogate general autophagy suggesting that, unlike 
mitophagy, this process might be complemented by 
another isoform of ULK, ULK2 [16].
We observed induction of hepatic mitochondria bio-
genesis by T3-mediated stimulation of PGC1a and 
mitochondrial protein expression. The latter proteins 
increased their accumulation when autophagy was 
blocked suggesting that there was increased mitochon-
drial turnover involving both mitophagy and mitochon-
drial synthesis. The transcriptional expression of several 
genes involved in mitophagy, Bnip, Nix, ULK1, p62, and 
LC3 mRNAs also were induced by T3. Additionally, the 
master regulator of autophagy and lysosomal genes, 
Transcription factor EB (TFEB) as well as PGC1a, Tfam, 
and Cox 4 mRNAs were induced by T3.
Tissue‑specific hypothyroidism in NAFLD
We examined livers from mice fed a methionine and cho-
line deficient (MCD) diet for 12  weeks and found that 
the highly sensitive TH-responsive gene, Deiodinase 1 
(DIO1), a deiodinase enzyme that converts T4 to T3, was 
significantly reduced in livers of MCD-fed rats compared 
to livers from control animals fed normal chow diet. 
Moreover, the MCD fed group exhibited grade 2 steato-
hepatitis on histology. We then measured intrahepatic 
T3, T4, and rT3 concentrations in livers from MCD-fed 
rats vs. rats fed normal chow diet. For the MCD fed rats, 
hepatic T3 concentration was significantly decreased, 
rT3 whereas hepatic T4, and rT3 concentrations were not 
changed (Sinha and Yen, unpublished data). In pilot stud-
ies in these rats, we found that DIO1 as well as OATP1 
and MCT8 (thyroid hormone transporters) mRNA 
expression were decreased suggesting that intrahepatic 
hypothyroidism may be a feature of, as well as a contribu-
tor towards, the development of NASH in these rats.
Consistent with our data, two previous studies showed 
that T3 or TH analogs decreased hepatosteatosis in 
mouse and rat models [5, 6]. In order to assess whether 
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T3 decreased lipotoxicity, a common feature of steato-
hepatitis, we examined the effects of TH on palmitate-
induced cell death. Preliminary results showed palmitate 
markedly increased cleaved caspase 3 in TRβ-HepG2 
cells, and this was attenuated by co-treatment with T3. 
Palmitate itself induced an increase in autophagy. How-
ever, the improvement in cell survival provided by T3 
also was accompanied by a further increase in autophagy. 
Although palmitate increased oxidative phosphorylation 
as measured by the Seahorse XF Analyzer available in our 
laboratory, T3 further increased oxidative phosphoryla-
tion (Sinha and Yen, unpublished results.). These results 
suggest that induction of lipophagy and β-oxidation by 
T3 may protect against lipotoxicity due to toxic lipids 
derived from excessive intracellular palmitate such as 
such as ceramides or diacylglycerol. On the basis of the 
foregoing pre-clinical data, we recently have initiated a 
pilot clinical study on the effects of low dose levothyrox-
ine therapy in reducing hepatic fat content and improv-
ing glucose control in diabetic Chinese male patients 
with hepatosteatosis. Patients are treated with low dose 
levothyroxine for 4  months, with their liver fat content 
measured both before and after treatment by MRI spec-
troscopy. Currently, we are in the middle  of the enroll-
ment of patients for our study.
Role of SIRT1 on T3‑mediated autophagy
We also have shown that a subset of forkhead box pro-
tein O1 (FOXO1) target genes, including those involved 
in gluconeogenesis, are co-regulated by T3 through 
its metabolic activation of SIRT1 and its regulation 
of downstream deacetylation and dephosphorylation 
of FOXO1 [19, 20]. SIRT1 is a deactylase that can be 
activated by increased NAD+  concentration, and thus 
can act as an intracellular energy sensor to modulate 
the transcriptional activity by both TH and FOXO1 
[21]. Besides its critical role in gluconeogenesis, we 
also have found that SIRT1 is required for TH-medi-
ated autophagy by virtue of its ability to stimulate the 
expression of target genes involved in autophagy as well 
as deacetylate ATG proteins. Thus, SIRT1 plays vital 
roles in in initiating and maintaining the autophagy 
that is required for β-oxidation of fatty acids as well 
as mitophagy by TH. In this connection, mitochon-
dria degeneration has been associated with metabolic 
disorders and aging. Thus, the maintenance of normal 
mitophagy may be a crucial aspect in preventing cell 
death in tissues such as the pancreas and liver in dia-
betes. Furthermore, it is possible that maintaining tis-
sue-specific euthyroidism may promote normal lipid 
metabolism as well as preserve mitochondrial func-
tion in the liver. Indeed, the expression of target genes 
involved in lipid metabolism that are regulated by TH 
are decreased in liver samples from patients undergoing 
bariatric surgery [7].
Conclusions
In summary, we believe that our studies to elucidate the 
mechanisms of hepatic mitochondrial turnover by TH 
and SIRT1 and the role of autophagy in NAFLD, will lead 
(See figure on previous page.) 
Fig. 1 T3 increases autophagy and mitophagy in hepatic cells. a Model showing how mitochondria-specific mRFP-GFP protein detects mitophagy. 
b Monitoring mitophagic flux using dual fluorescence p-mito-mRFP-EGFP reporter (pAT016) in HepG2 cells. Lysosomal delivery of the tandem 
fusion protein Mito-mRFP-EGFP along with entire mitochondria results in differential quenching and degradation of the two individual fluoro-
chromes, thus allowing for visual analysis of mitophagic flux. TRβ1-HepG2 cells transiently expressing Mito-mRFP-EGFP were treated with 1 nM or 
100 nM T3 for 48 h followed by visualization using confocal microscopy (40× magnification). Nuclei were stained with DAPI (blue). In the images, 
fluorescence signals indicates the expression of Mito-mRFP-EGFP targeting mitochondria: yellow color no mitophagy or normal cytosolic mito-
chondria, red color mitophagy or mitochondria inside lysosomes. c Quantitative analysis of the RFP (red-only) fluorescence to denote % mitophagy 
was done. Quantification of images (at least 20 transfected cells per each sample in 3 different fields) was conducted with ImageJ software. Bars 
represent the mean of the respective individual ratios ± SD (*p < 0.05). d Electron micrograph of primary mouse hepatocytes treated with T3. EM of 
untreated control and T3-treated (100 nM/24 h) mouse hepatocytes showing increased mitophagy (Denoted by arrows showing autophagosomes 
containing mitochondria) under T3 treatment. Scale bar 1 µm and in enlarged figures are 0.2 µm. e Bar graphs showing % of autophagosomes (AVs) 
containing mitochondria in control and T3-treated primary mouse hepatocytes based on EM micrograph images. Scoring was done by counting 
10–15 different autophagic vesicles in 5 random fields per condition (n = 3, *p < 0.05. Adapted from Ref. [16], Figs. 4 and 6
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to better understanding of the role of hormones and their 
potential dysregulation in the pathogenesis and progres-
sion of this condition. This information could lead to bet-
ter diagnosis and treatments for NAFLD as well as other 
metabolic disorders.
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Fig. 2 Mitophagy proteins translocate to mitochondria and are necessary for T3 stimulation of mitophagy. a Immunoblot showing mitochondrial 
protein ubiquitination and localization of ULK1, p62, LC3-II, and Drp1 proteins in isolated mitochondrial fraction from T3 (100 nM/48 h)-treated TRβ1-
HepG2 cells. Purity/enrichment of the mitochondrial fraction (Mito) was verified by the absence of β-Tubulin (cytosolic) and LAMP-1 (lysosomal) 
relative to its level in the whole cell lysate (WCL) for the same amount of VDAC levels. b TRβ-HepG2 cells transiently expressing Mito-mRFP-EGFP 
were treated with 100 nM T3 for 48 h with or without ULK1 KD followed by visualization using confocal microscopy (40× magnification). Nuclei 
were stained with DAPI (blue). In the images, fluorescence signals indicate the expression of Mito-mRFP-EGFP targeting mitochondria: yellow color 
no mitophagy, red color mitophagy. c Quantitative analysis of the RFP (red) fluorescence to denote  % mitophagy. Quantification of images (at least 
10 transfected cells per each sample in 3 different fields) was conducted with ImageJ software. Bars represent the mean of the respective individual 
ratios ± SD (*p < 0.05). Adapted from Ref. [16], Fig. 9
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